COVID-19 has created challenges for most med-tech companies, but Becton Dickinson (BDX) ("BD") already had a lot of balls to juggle before COVID-19 disrupted hospital and physician procedure counts. While COVID-19 has itself created some opportunities in testing and the pre-filled syringe business, longer-term issues in the drug-coated balloon and drug pump businesses have caused some headaches for management.
Becton Dickinson has actually been a pretty meaningful sector underperformer since announcing the deal for Bard back in 2017, though the shares are relatively popular with the sell-side on assumptions that BD will benefit from increased COVID-19 testing volumes, an eventual vaccine, resumption of elective procedures, and an eventual resolution of its Alaris pump recall. Although I don’t value BD has highly as those on the sell-side, I do believe the shares are still somewhat undervalued today.
Read the full article here:
Becton Dickinson Trying To Leverage COVID-19 Opportunities While Fixing Some Longer-Term Issues
No comments:
Post a Comment